Bank of America CORP /DE/ (NYSE:BAC), which is a ten-percent owner of ENvue Medical, Inc. (FEED), reported the sale of 2,918 shares of ENvue common stock on February 2, 2026, according to a Form 4 filing with the U.S. Securities and Exchange Commission. The shares were sold at prices between $3.04 and $3.07, producing aggregate proceeds of $8,905.
Following the transaction, Bank of America continues to hold an indirect position of 231,038 ENvue shares. ENvue’s shares were trading at $3.12 at the time of the reporting, and an InvestingPro analysis cited in the disclosure indicates the company may be undervalued even as it carries a weak financial health score and is classified as a micro-cap with a market capitalization of $3.5 million.
Separately from the insider sale, ENvue Medical has announced several corporate developments intended to advance commercialization and market access for its feeding-tube placement products.
The company said it entered into a partnership with U-Deliver to distribute ENvue’s ENFit Syringes across the United States, leveraging digital and wholesale channels to broaden availability. In addition, ENvue appointed Marc Waldman as Vice President of Commercial to lead commercialization efforts in the U.S. The company noted Waldman’s more than 35 years in the medical device sector and cited his prior role in growing Avanos Medical’s revenue from $39 million to $70 million.
ENvue also amended its 2024 Long Term Incentive Plan to align with Israeli tax regulations and to reflect updates connected to the company’s recent renaming from NanoVibronix, Inc. to ENvue Medical. The company indicated the name change and related adjustments are part of its repositioning.
On the reimbursement and international front, ENvue reported that its UroShield Kit has been added to the NHS Drug Tariff in the United Kingdom, which enables nationwide prescription reimbursement. The company also secured an initial purchase order from Peak Medical, supporting the U.K. rollout.
ENvue Medical announced a broader rebranding effort and noted that its common stock now trades under the ticker symbol FEED on the Nasdaq Capital Market. The company indicated these moves are part of a strategic focus on the ENvue feeding-tube placement system, described as an electromagnetic navigation platform.
Key points
- Bank of America sold 2,918 ENvue shares on February 2, 2026, for $8,905 total, and still holds 231,038 shares - impact on capital markets and investor monitoring of insider activity.
- ENvue is advancing U.S. commercialization with a national distribution agreement for ENFit Syringes and the hiring of Marc Waldman as VP of Commercial - relevant to medical device and healthcare supply chains.
- Reimbursement and international expansion progressed via NHS Drug Tariff listing for the UroShield Kit and an initial purchase order from Peak Medical - important for payment access and hospital procurement.
Risks and uncertainties
- The company is characterized as having a weak financial health score and a micro-cap market value of $3.5 million, which could affect liquidity and investor risk - relevant to capital markets and small-cap equity investors.
- Insider selling, even if modest, and ongoing commercialization execution introduce uncertainty about near-term operational progress and market uptake - relevant to the medical device sector and hospital purchasing cycles.
- Regulatory and tax alignment steps, such as the LTIP amendment for Israeli tax laws, introduce administrative and compliance considerations that may affect compensation and governance - relevant to corporate governance and cross-border tax compliance.